Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Avadel Pharmaceuticals (Nasdaq: AVDL) announced on October 13, 2025 that its Compensation Committee approved inducement option awards for seven new employees totaling 161,600 ordinary shares under the company's 2021 Inducement Plan.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Avadel Pharmaceuticals (Nasdaq: AVDL) announced on October 13, 2025 that its Compensation Committee approved inducement option awards for seven new employees totaling 161,600 ordinary shares under the company's 2021 Inducement Plan.
The non-statutory options carry a 10-year term and vest over four years with 25% vesting after one year and 25% on each of the second, third, and fourth anniversaries of each employee's start date. Awards are granted as inducements under Nasdaq Listing Rule 5635(c)(4) and are subject to the 2021 Inducement Plan and individual award agreements.
Details
News Market Reaction – AVDL
On Oct 14, the first trading day after this news, AVDL closed 1.20% above the previous close.
Data tracked by StockTitan Argus for the Oct 14 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DUBLIN, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to seven (7) new employees to purchase 161,600 ordinary shares under Avadel’s 2021 Inducement Plan. The awards were granted as an inducement material to the employee’s acceptance of employment with Avadel in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a ten-year term and vest over four years, with
About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Avadel’s commercial product, LUMRYZ™, was approved by the U.S. Food & Drug Administration (FDA) as the first and only once-at-bedtime oxybate for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years and older with narcolepsy. For more information, please visit www.avadel.com.
Investor Contact:
Austin Murtagh
Precision AQ
Austin.Murtagh@precisionAQ.com
(212) 698-8696
Media Contact:
Alyssa Ramirez
Real Chemistry
aramirez@realchemistry.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.